

## DIRECTOR APPOINTMENT AND RESIGNATION

Melbourne, Australia – Nexalis Therapeutics Ltd (“**NX1**” or “the **Company**”) advises of the resignation of Dr Ron Wise as a director of the Company and the appointment of Mr James Barrie as a director of the Company. These changes are effective from 12 May 2026.

Dr Wise has informed the Board of his resignation due to the significant recent increase in time commitment related to his family business. In the interim, whilst a new director is recruited, James Barrie, NX1’s Company Secretary, has consented to act as a director on an interim basis. Mr Barrie, who has acted as a director of the Company on an interim basis previously, is a professional Company Secretary and Director.

The Board thanks Dr Wise for his contribution as a director since his appointment in 2024 and wishes him every success in his future endeavours. An Appendix 3Z for Dr Wise and Appendix 3X for Mr Barrie are attached to this announcement.

Authorised for release by the Board of Directors.

### For further information:

[www.nexalistherapeutics.com](http://www.nexalistherapeutics.com)

James Barrie, Company Secretary

T: +61 3 9070 1221

E: [investors@nexalistherapeutics.com](mailto:investors@nexalistherapeutics.com)

### Investor relations

Matthew Wright

NWR Communications

M: 0451 896 420

E: [matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)

### ABOUT NEXALIS THERAPEUTICS LTD (ASX: NX1)

Nexalis Therapeutics Ltd is an Australian Clinical Stage Drug Development Company that is developing rapid onset therapies to address unmet medical needs in pain management and mental health sectors. The Company has secured a funding partner with a facility of up to \$52.3m to accelerate the development of IRX-211 to treat Breakthrough Cancer Pain (**BTcP**), IRX-616a to treat Panic Disorder (**PD**) and SRX-25 for the treatment of Treatment-Resistant Depression (**TRD**).

The overarching goal is to pursue U.S. FDA approval and registration using rapid and cost-effective regulatory pathways, such as 505(b)(2).

There is a significant economic opportunity for NX1 and the Company’s shareholders, with the clinical indications under investigation carefully selected in consultation with regulatory authorities. Bringing new approved medications to market will address critical gaps whereby there’s currently mismatched treatment options that can carry dependency concerns.

### CONTACT US

#### NEXALIS THERAPEUTICS

T: +61 3 9070 1221 | E: [investors@nexalistherapeutics.com](mailto:investors@nexalistherapeutics.com) | W: <https://www.nexalistherapeutics.com>

# Appendix 3X

## Initial Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

|                                                 |
|-------------------------------------------------|
| <b>Name of entity: NEXALIS THERAPEUTICS LTD</b> |
| <b>ACN: 611 845 820</b>                         |

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

|                            |              |
|----------------------------|--------------|
| <b>Name of Director</b>    | JAMES BARRIE |
| <b>Date of appointment</b> | 12 MAY 2026  |

### Part 1 - Director's relevant interests in securities of which the director is the registered holder

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

|                                         |
|-----------------------------------------|
| <b>Number &amp; class of securities</b> |
| NIL                                     |

## Appendix 3X

### Initial Director's Interest Notice

---

#### Part 2 – Director's relevant interests in securities of which the director is not the registered holder

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

| Name of holder & nature of interest                                              | Number & class of Securities                                             |
|----------------------------------------------------------------------------------|--------------------------------------------------------------------------|
| Note: Provide details of the circumstances giving rise to the relevant interest. | .                                                                        |
| FESTING MILL PTY LTD ATF<br>PETER PAN TRUST                                      | 524,792 Ordinary Shares<br>25,000 Unlisted options @\$0.042 Exp 23/12/27 |
| <i>Mr Barrie is a beneficiary of this entity</i>                                 |                                                                          |

#### Part 3 – Director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

|                                                          |     |
|----------------------------------------------------------|-----|
| Detail of contract                                       | N/A |
| Nature of interest                                       | N/A |
| Name of registered holder<br>(if issued securities)      | N/A |
| No. and class of securities to<br>which interest relates | N/A |

---

+ See chapter 19 for defined terms.

# Appendix 3Z

## Final Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

|                                                 |
|-------------------------------------------------|
| <b>Name of entity: NEXALIS THERAPEUTICS LTD</b> |
| <b>ACN: 611 845 820</b>                         |

We (the entity) give ASX the following information under listing rule 3.19A.3 and as agent for the director for the purposes of section 205G of the Corporations Act.

|                                                 |                  |
|-------------------------------------------------|------------------|
| <b>Name of director</b>                         | DR RON WISE      |
| <b>Date of last notice</b>                      | 17 FEBRUARY 2024 |
| <b>Date that director ceased to be director</b> | 12 MAY 2026      |

### Part 1 – Director's relevant interests in securities of which the director is the registered holder

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

|                                         |
|-----------------------------------------|
| <b>Number &amp; class of securities</b> |
| Nil                                     |

## Appendix 3Z

### Final Director's Interest Notice

---

#### Part 2 – Director's relevant interests in securities of which the director is not the registered holder

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

| Name of holder & nature of interest<br><small>Note: Provide details of the circumstances giving rise to the relevant interest</small> | Number & class of securities                                                                                                                                          |
|---------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Sassey Pty Ltd <Sassey A/C><br>Sassey Pty Ltd <Avago Super Fund A/C><br><br><i>Dr Wise is a beneficiary of both entities</i>          | 4,006,302 Fully paid ordinary shares<br>1,833,762 Performance Rights<br>500,000 Unlisted Options @\$0.12 Exp 7/7/28<br>756,659 Unlisted options @\$0.042 Exp 23/12/27 |

#### Part 3 – Director's interests in contracts

|                                                       |     |
|-------------------------------------------------------|-----|
| Detail of contract                                    | N/A |
| Nature of interest                                    | N/A |
| Name of registered holder (if issued securities)      | N/A |
| No. and class of securities to which interest relates | N/A |

---

+ See chapter 19 for defined terms.